- Full Year 2023 Ucb SA Earnings Call TranscriptFeb 28, 2024€105 (+8.09%)Earnings
- Half Year 2023 Ucb SA Earnings Call TranscriptJul 27, 2023€80.86 (+0.12%)Earnings
- Ucb SA Update on BKZ US Review and Rystiggo US Approval Call TranscriptJun 27, 2023
- Full Year 2022 Ucb SA Earnings Call TranscriptFeb 22, 2023€80.98 (+2.38%)Earnings
- Full Year 2021 UCB SA Earnings Call TranscriptFeb 24, 2022€91.9 (+4.08%)Earnings
- UCB SA to Acquire Zogenix Inc Capital Markets Call TranscriptJan 19, 2022
- Half Year 2021 UCB SA Earnings Call TranscriptJul 29, 2021€91.6 (+1.42%)Earnings
- Full Year 2020 UCB SA Earnings Call TranscriptFeb 25, 2021€86 (+5.76%)Earnings
- UCB SA at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2021
- Ucb SA Analysts and Investors Conference Call TranscriptNov 12, 2020
- Q2 2020 Ucb SA Earnings Call TranscriptJul 27, 2020€110.75 (+0.73%)Earnings
- Full Year 2019 Ucb SA Earnings Call TranscriptFeb 20, 2020€92.28 (+3.11%)Earnings
- Ucb SA to Acquire Ra Pharmaceuticals Inc Call TranscriptOct 10, 2019
- Q2 2019 Ucb SA Earnings Call TranscriptJul 25, 2019€71.34 (-5.03%)Earnings
- Q4 2018 Ucb SA Earnings Call TranscriptFeb 28, 2019€73.68 (-4.29%)Earnings
Full Year 2023 Ucb SA Earnings Call Transcript
Good morning, good afternoon and good evening. Welcome to the UCB Full Year 2023 Capital Markets Call. This is Antje from the Investor Relations team.
Before I introduce you to the agenda and hand over to the speakers today, I'd like to make some remarks. This presentation and the following Q&A session are intended for institutional capital market participants. If you're not, please disconnect now. This video conference is being recorded. This presentation and the following Q&A session are covered by the disclaimer and safe harbor statement as stated on the Slide 2 of the slide deck, please read this carefully. You can find the presentation in our download center in case on our website in case you would dial in by phone.
With this, I'd like you to introduce to our speakers for today, our CEO, Jean-Christophe Tellier; Emmanuel Caeymaex, Executive Vice President, Immunology and Head of the U.S. Iris Low-Friedrich, Chief Medical Officer; and the CFO, Sandrine Dufour. In the Q&A session, not only the speakers will be there to answer your
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)